Your browser doesn't support javascript.
loading
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome.
Tantawy, Azza A; Elsherif, Nayera H K; Elsayed, Solaf M; Ali, Heba G A; Makkeyah, Sara M; Elsantiel, Hisham I E; de Saint Basile, Geneviève; Ragab, Iman A.
Afiliación
  • Tantawy AA; Pediatric Hematology and Oncology, Children's Hospital, Ain Shams University, Cairo, Egypt.
  • Elsherif NHK; Pediatric Hematology and Oncology, Children's Hospital, Ain Shams University, Cairo, Egypt.
  • Elsayed SM; Medical Genetics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Ali HGA; Pediatric Hematology and Oncology, Children's Hospital, Ain Shams University, Cairo, Egypt.
  • Makkeyah SM; Pediatric Hematology and Oncology, Children's Hospital, Ain Shams University, Cairo, Egypt.
  • Elsantiel HIE; Pediatric Hematology and Oncology, Children's Hospital, Ain Shams University, Cairo, Egypt.
  • de Saint Basile G; Université de Paris, Imagine Institute, Paris, France.
  • Ragab IA; Centre d'Etude des Déficits Immunitaires, AP-HP, Hôpital Necker-Enfants Malades, Paris, France.
Expert Rev Hematol ; 17(4-5): 153-163, 2024.
Article en En | MEDLINE | ID: mdl-38597207
ABSTRACT

BACKGROUND:

Hemophagocyticlymphohistiocytosis (HLH) is a spectrum of immune activation which could be genetically determined, or secondary to an underlying illness. Our aim was to present the clinico-genetic aspects of HLH among Egyptian children and to evaluate the patterns of reactivation and outcome with illustrations of overlap manifestations. RESEARCH DESIGNAND

METHODS:

We retrospectively collected the data of 55 patients with HLH, registered at Ain Shams University Children's Hospital,Cairo, Egypt.

RESULTS:

Median age at diagnosis was 19 months (range 2-180), 33 patients (60%) fulfilled the diagnostic HLH criteria at presentation. Fourteen (25.45%) patients had secondary HLH, 15 (27.27%) patients had genetically documented familial HLH (11 had variants in UNC13D gene and one in PRF1 gene), 3 had Griscelli and Chediak-Higashi syndromes. Sixteen patients (29.1%) had reactivations, 8 (50%) of them had molecularly confirmed HLH. We report the death of 40 patients, the median duration from the diagnosis to death of 5 months mostly due to disease activity.

CONCLUSIONS:

This study confirms that the nonspecific signs and symptoms of HLH are challenging. Genetic testing, though expensive and sophisticated, is integral for the diagnosis. The difficulty in finding non-related donors for stem cell transplantation and the early reactivations are the causes of the inferior outcome.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfohistiocitosis Hemofagocítica País/Región como asunto: Africa Idioma: En Revista: Expert Rev Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfohistiocitosis Hemofagocítica País/Región como asunto: Africa Idioma: En Revista: Expert Rev Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article